616 related articles for article (PubMed ID: 30979742)
1. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
Coats S; Williams M; Kebble B; Dixit R; Tseng L; Yao NS; Tice DA; Soria JC
Clin Cancer Res; 2019 Sep; 25(18):5441-5448. PubMed ID: 30979742
[TBL] [Abstract][Full Text] [Related]
2. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
Ma H; Sawas A
Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
[TBL] [Abstract][Full Text] [Related]
4. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
Herrera AF; Molina A
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates: present and future.
Beck A; Reichert JM
MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
[TBL] [Abstract][Full Text] [Related]
7. Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ; Luo S; Twomey JD; Zhang B
MAbs; 2021; 13(1):1951427. PubMed ID: 34291723
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
[TBL] [Abstract][Full Text] [Related]
9. Recent advances of antibody drug conjugates for clinical applications.
Zhao P; Zhang Y; Li W; Jeanty C; Xiang G; Dong Y
Acta Pharm Sin B; 2020 Sep; 10(9):1589-1600. PubMed ID: 33088681
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.
Martin C; Kizlik-Masson C; Pèlegrin A; Watier H; Viaud-Massuard MC; Joubert N
MAbs; 2018; 10(2):210-221. PubMed ID: 29239690
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C; Morganti S; Curigliano G
J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
[TBL] [Abstract][Full Text] [Related]
13. Calicheamicin Antibody-Drug Conjugates with Improved Properties.
Vollmar BS; Frantz C; Schutten MM; Zhong F; Del Rosario G; Go MAT; Yu SF; Leipold DD; Kamath AV; Ng C; Xu K; Dela Cruz-Chuh J; Kozak KR; Chen J; Xu Z; Wai J; Adhikari P; Erickson HK; Dragovich PS; Polson AG; Pillow TH
Mol Cancer Ther; 2021 Jun; 20(6):1112-1120. PubMed ID: 33722856
[TBL] [Abstract][Full Text] [Related]
14. [Antibody-drug conjugates: a new therapeutic class?].
Chofflon I; Dietrich PY; Thang NN
Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Pondé N; Aftimos P; Piccart M
Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugate technology development for hematologic disorders.
Bander NH; Czuczman MS; Younes A
Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
Chu Y; Zhou X; Wang X
J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
[TBL] [Abstract][Full Text] [Related]
18. Linked-in: design and efficacy of antibody drug conjugates in oncology.
Feld J; Barta SK; Schinke C; Braunschweig I; Zhou Y; Verma AK
Oncotarget; 2013 Mar; 4(3):397-412. PubMed ID: 23651630
[TBL] [Abstract][Full Text] [Related]
19. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
20. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
